Skip to main content
Erschienen in: Acta Diabetologica 4/2012

01.08.2012 | Original Article

Structural damage in diabetic nephropathy is associated with TNF-α system activity

verfasst von: José Manuel Fernández-Real, Joan Vendrell, Isabel García, Wifredo Ricart, Martí Vallès

Erschienen in: Acta Diabetologica | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

In experimental animal studies, tumour necrosis factor-α (TNF-α) contributed to renal hypertrophy during diabetes, and antibodies against TNF-α have led to improved histological lesions in animals with nephrotoxicity and diabetic nephropathy. We aimed to evaluate TNF-α system activity in association with renal histology in patients with type 2 diabetes. This is a prospective, cross-sectional study of 22 patients with type 2 diabetes (16 men), 13 with microalbuminuria and 9 with normoalbuminuria. Plasma-soluble TNF-α receptor 1 and 2 (sTNFR1 and sTNFR2) concentrations were used as surrogates of TNF-α system activity. Glomerular filtration rate (GFR) was analysed using I125-Iodothalamine. Albumin excretion rate (AER) and a renal biopsy were performed in all subjects. AER did not associate significantly with mesangial expansion or interstitial fraction in these subjects (r < 0.12, P > 0.5). AER was also not associated with either sTNFR1 or sTNFR2 levels. However, after controlling for GFR, the correlation between AER and sTNFR1 became significant (r = 0.47, P = 0.03). sTNFR1 correlated with age (r = 0.65, P < 0.001), mesangial expansion (r = 0.59, P = 0.004) and interstitial fraction (r = 0.58, P = 0.005). After controlling for age, body mass index and blood pressure, the association of TNFR1 with mesangial expansion persisted significant. Circulating sTNFR2 concentrations were not significantly associated with histological changes. In summary, structural kidney damage in patients with type 2 diabetes is associated with TNF-α system activity and specifically with plasma sTNFR1 concentrations.
Literatur
1.
Zurück zum Zitat Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922 Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922
2.
Zurück zum Zitat Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012PubMedCrossRef Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012PubMedCrossRef
3.
Zurück zum Zitat Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548PubMedCrossRef Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548PubMedCrossRef
4.
Zurück zum Zitat Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118CrossRef Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118CrossRef
5.
Zurück zum Zitat Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463PubMedCrossRef Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463PubMedCrossRef
6.
Zurück zum Zitat Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34 Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34
7.
Zurück zum Zitat Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324PubMedCrossRef Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324PubMedCrossRef
8.
Zurück zum Zitat Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762PubMedCrossRef Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762PubMedCrossRef
9.
Zurück zum Zitat Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print) Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print)
10.
Zurück zum Zitat Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print) Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print)
11.
Zurück zum Zitat Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print) Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print)
12.
Zurück zum Zitat Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142PubMedCrossRef Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142PubMedCrossRef
13.
Zurück zum Zitat Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394PubMedCrossRef Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394PubMedCrossRef
14.
Zurück zum Zitat Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410PubMed Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410PubMed
15.
Zurück zum Zitat Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329PubMedCrossRef Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329PubMedCrossRef
16.
Zurück zum Zitat Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642PubMedCrossRef Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642PubMedCrossRef
17.
Zurück zum Zitat Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697PubMedCrossRef Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697PubMedCrossRef
18.
Zurück zum Zitat DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121PubMed DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121PubMed
19.
Zurück zum Zitat Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962PubMedCrossRef Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962PubMedCrossRef
20.
Zurück zum Zitat Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552PubMed Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552PubMed
21.
Zurück zum Zitat Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232PubMedCrossRef Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232PubMedCrossRef
22.
Zurück zum Zitat Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636PubMedCrossRef Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636PubMedCrossRef
23.
Zurück zum Zitat Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51PubMedCrossRef Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51PubMedCrossRef
24.
Zurück zum Zitat Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218PubMedCrossRef Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218PubMedCrossRef
25.
Zurück zum Zitat Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672PubMedCrossRef Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672PubMedCrossRef
26.
Zurück zum Zitat Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546PubMedCrossRef Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546PubMedCrossRef
27.
Zurück zum Zitat Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121PubMed Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121PubMed
Metadaten
Titel
Structural damage in diabetic nephropathy is associated with TNF-α system activity
verfasst von
José Manuel Fernández-Real
Joan Vendrell
Isabel García
Wifredo Ricart
Martí Vallès
Publikationsdatum
01.08.2012
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 4/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0349-y

Weitere Artikel der Ausgabe 4/2012

Acta Diabetologica 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.